Erlotinib
AA Abdelgalil, HM Al-Kahtani, FI Al-Jenoobi - Profiles of Drug Substances …, 2020 - Elsevier
Abstract Erlotinib (OSI-774), marketed by Genentech as Tarceva®, is anticancer drug
approved by US-FDA for the treatment of Non-Small Cell Lung Cancer (NSCLC) and …
approved by US-FDA for the treatment of Non-Small Cell Lung Cancer (NSCLC) and …
A review of erlotinib–an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor
R Iyer, A Bharthuar - Expert opinion on pharmacotherapy, 2010 - Taylor & Francis
Importance of the field: The epidermal growth factor receptor (EGFR) is a cell surface
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …
Erlotinib hydrochloride.
JD Minna, J Dowell - Nature Reviews. Drug Discovery, 2005 - europepmc.org
Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a
class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor …
class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor …
Erlotinib (Tarceva): an update on the clinical trial program
RS Herbst - Seminars in oncology, 2003 - Elsevier
Erlotinib HCI (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
quinazoline-based agent that competes with adenosine triphosphate for binding with the …
quinazoline-based agent that competes with adenosine triphosphate for binding with the …
Erlotinib hydrochloride.
J Dowell, JD Minna, P Kirkpatrick - Nature Reviews Drug Discovery, 2005 - nature.com
Abstract Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a
member of a class of targeted anticancer drugs that inhibit the activity of the epidermal …
member of a class of targeted anticancer drugs that inhibit the activity of the epidermal …
A review of erlotinib and its clinical use
PA Tang, MS Tsao, MJ Moore - Expert opinion on pharmacotherapy, 2006 - Taylor & Francis
Erlotinib is an orally available, reversible tyrosine kinase inhibitor of the epidermal growth
factor receptor. Encouraging activity as a single agent and in combination with other …
factor receptor. Encouraging activity as a single agent and in combination with other …
Preclinical studies with erlotinib (Tarceva)
RW Akita, MX Sliwkowski - Seminars in oncology, 2003 - Elsevier
Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
Erlotinib: Small-molecule targeted therapy in the treatmentof non-small-cell lung cancer
J Smith - Clinical therapeutics, 2005 - Elsevier
BACKGROUND:: Erlotinib is an oral tyrosine kinase inhibitor, 1026 targeting the human
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …
Erlotinib OSI/Roche/Genentech.
TE Kim, JR Murren - Current opinion in investigational drugs …, 2002 - europepmc.org
Erlotinib (CP-358774, OSI-774, Tarceva), a quinazoline derivative, is an orally active
epidermal growth factor receptor tyrosine kinase inhibitor under development jointly by …
epidermal growth factor receptor tyrosine kinase inhibitor under development jointly by …
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor
A high-performance liquid-chromatographic (HPLC) assay with UV detection has been
developed for the quantitative determination of erlotinib (OSI-774) in human plasma …
developed for the quantitative determination of erlotinib (OSI-774) in human plasma …